Berlin, Germany – Health officials in California have confirmed the state’s first case of clade I mpox, a variant of the virus currently circulating in Central and Eastern Africa. This marks the first instance of this particular strain being identified in the United States, prompting increased surveillance and a reminder of ongoing global health concerns surrounding mpox. While the risk to the general public remains low, the case underscores the importance of continued vigilance and adherence to preventative measures.
The California Department of Public Health confirmed the case through laboratory testing, noting that the individual had recently traveled from Eastern Africa. The patient, who has not been publicly identified, received treatment shortly after returning to the U.S. And is currently isolating at home, with symptoms reportedly improving. Specimens have been sent to the Centers for Disease Control and Prevention (CDC) for further analysis and characterization of the virus. Public health authorities are actively working to identify and follow up with any potential contacts who may have been exposed.
This development comes more than two years after the initial global mpox outbreak in 2022, primarily linked to clade IIb, which led to widespread concern and a public health response. The emergence of clade I mpox in the U.S., though currently limited to this single case, highlights the continued evolution of the virus and the potential for new variants to emerge. Understanding the differences between these clades is crucial for effective public health strategies.
Understanding Mpox Clades and the Current Situation
Mpox, formerly known as monkeypox, is caused by a virus that exists in two main clades: clade I and clade II. Both clades can be spread, treated and prevented using similar methods. But, historically, clade I mpox has been associated with more severe illness and higher mortality rates compared to clade II. Recent data suggests that infections from the current clade I outbreak may not be as clinically severe as in previous outbreaks, with death rates potentially lower in countries with robust healthcare systems.
The current outbreak of clade I mpox is concentrated in Central and Eastern Africa, with over 46,000 cases reported. Travel-associated cases of clade I, specifically subclade Ib, have also been identified in several European countries, including Germany, India, Kenya, Sweden, Thailand, Zimbabwe, and the United Kingdom. The CDC has been actively monitoring the situation globally and working with international partners to prevent further spread. In the United States, sporadic cases of clade II mpox continue to circulate, with a slight uptick observed during the summer of 2025, some linked to outbreaks in Sierra Leone and Liberia.
The CDC emphasizes that casual contact during travel is unlikely to pose a significant risk of transmission. However, they continue to recommend that clinicians request expedited clade-specific testing for any suspected cases of clade I mpox in individuals with a recent travel history to affected areas in Central and Eastern Africa. The agency is also utilizing wastewater surveillance to monitor for the presence of both clades of the mpox virus in communities across the country, providing an early warning system for potential outbreaks.
Symptoms and Transmission of Mpox
Mpox symptoms typically begin with a rash that can appear on various parts of the body, including the hands, feet, chest, face, mouth, and genitals. The incubation period for the virus ranges from 3 to 17 days, during which individuals may not exhibit any symptoms but can still be contagious. The rash often progresses through distinct stages, starting as flat, discolored spots that eventually develop into fluid-filled blisters. These blisters can then scab over and eventually heal.
Transmission of mpox occurs through close, direct contact with the rash, scabs, or body fluids of an infected person. It can also be spread through contact with contaminated materials, such as clothing, bedding, or shared items like toothbrushes or sex toys. Respiratory secretions may also play a role in transmission, particularly during prolonged, face-to-face contact. The CDC stresses the importance of avoiding close contact with individuals exhibiting symptoms and practicing good hygiene to minimize the risk of infection.
Preventative Measures and Vaccination
Public health officials are urging individuals to take preventative measures to protect themselves from mpox. These include avoiding close contact with people who are sick, refraining from contact with contaminated materials, and practicing good hand hygiene. For those eligible, the CDC recommends receiving both recommended doses of the mpox vaccine, which has proven effective in preventing infection and reducing the severity of illness. Information on vaccine eligibility and availability can be found on the CDC website.
The CDC has leveraged its experience from the 2022 global outbreak of clade II mpox to adapt existing public health systems and structures to respond effectively to any potential outbreaks of clade I mpox in the United States. This includes issuing guidance for travelers to countries in Central and Eastern Africa and providing support to state and local health departments in conducting surveillance and contact tracing. The agency continues to collaborate with international partners to address the outbreak at its source and prevent further global spread.
What to Do If You Suspect Mpox
If you develop symptoms consistent with mpox, such as a rash, fever, headache, muscle aches, or swollen lymph nodes, it is crucial to seek medical attention promptly. Inform your healthcare provider about any recent travel history or potential exposure to individuals with mpox. Avoid close contact with others and isolate yourself until a diagnosis can be confirmed and appropriate medical guidance is received.
The CDC provides comprehensive information on mpox, including symptoms, prevention, and treatment options, on its website: https://www.cdc.gov/mpox/index.html. Staying informed and following public health recommendations are essential steps in protecting yourself and your community from this evolving health threat.
The anticipated overall risk of clade I mpox to the general population in the United States remains low, according to the CDC. However, continued monitoring, research, and public health preparedness are vital to mitigate any potential impact from this emerging variant. The CDC’s simulations suggest that close-contact transmissions are unlikely to result in a large number of cases, but ongoing vigilance is necessary.
Looking ahead, the CDC will continue to work closely with state and local health departments to monitor the situation, conduct genomic surveillance, and provide guidance to healthcare providers. Further updates and information will be released as the situation evolves. The agency encourages open communication and collaboration to ensure a coordinated and effective response to this ongoing public health challenge.
Key Takeaways:
- The first U.S. Case of clade I mpox has been confirmed in California, linked to travel from Eastern Africa.
- While the risk to the public remains low, the CDC is actively monitoring the situation and working with state and local health departments.
- Mpox symptoms include a characteristic rash, fever, and swollen lymph nodes.
- Vaccination is recommended for eligible individuals, and preventative measures include avoiding close contact with infected individuals and practicing good hygiene.
The situation is dynamic, and we will continue to provide updates as they become available. Please share this information with your networks and leave your thoughts and questions in the comments below.
Keep reading